Which parameters are key to monitor in patients on RAAS inhibitors and diuretics?

Which parameters are key to monitor in patients on RAAS inhibitors and diuretics?

• A. Serum potassium, creatinine/eGFR, blood pressure, uric acid, magnesium, and signs of dehydration.
• B. Hepatic enzymes and bilirubin.
• C. CBC and platelets.
• D. Urine sediment only.

Answer: (A)

Monitoring these drugs focuses on how they affect electrolytes, kidney function, and volume status. When RAAS inhibitors are used with diuretics, potassium tends to rise because aldosterone activity is reduced and the kidneys excrete less potassium. This makes checking serum potassium essential, especially in patients with chronic kidney disease, older adults, diabetes, or those taking other potassium-raising medications. Kidney function is also important to watch, because RAAS blockade can slightly raise creatinine or reduce estimated GFR as the intraglomerular pressure changes, and diuretics can cause volume depletion that alters perfusion. Regular blood pressure checks help ensure the combination lowers pressure without causing too much drop in BP or dizziness. Diuretics can raise uric acid levels, increasing gout risk, so monitoring uricemia is useful. Some diuretics, particularly loop diuretics, can cause magnesium loss, so magnesium levels may be relevant in patients at risk for low magnesium. Finally, dehydration signs—thirst, dry mucous membranes, orthostatic symptoms—reflect over-diuresis and volume depletion, which you want to avoid. Hepatic enzymes, bilirubin, CBC/platelets, or urine sediment aren’t primary concerns for this drug combo unless there’s another reason to check them, so they’re not the focus of routine monitoring.

Monitoring these drugs focuses on how they affect electrolytes, kidney function, and volume status. When RAAS inhibitors are used with diuretics, potassium tends to rise because aldosterone activity is reduced and the kidneys excrete less potassium. This makes checking serum potassium essential, especially in patients with chronic kidney disease, older adults, diabetes, or those taking other potassium-raising medications. Kidney function is also important to watch, because RAAS blockade can slightly raise creatinine or reduce estimated GFR as the intraglomerular pressure changes, and diuretics can cause volume depletion that alters perfusion. Regular blood pressure checks help ensure the combination lowers pressure without causing too much drop in BP or dizziness. Diuretics can raise uric acid levels, increasing gout risk, so monitoring uricemia is useful. Some diuretics, particularly loop diuretics, can cause magnesium loss, so magnesium levels may be relevant in patients at risk for low magnesium. Finally, dehydration signs—thirst, dry mucous membranes, orthostatic symptoms—reflect over-diuresis and volume depletion, which you want to avoid. Hepatic enzymes, bilirubin, CBC/platelets, or urine sediment aren’t primary concerns for this drug combo unless there’s another reason to check them, so they’re not the focus of routine monitoring.